According to Neurocrine Biosciences 's latest financial reports and stock price the company's current Operating Margin is 14.36%. At the end of 2022 the company had an Operating Margin of 14.37%.
Year | Operating Margin | Change |
---|---|---|
2022 | 14.37% | 60.62% |
2021 | 8.95% | -12.31% |
2020 | 10.20% | 72.9% |
2019 | 5.90% | 21.9% |
2018 | 4.84% | -105.49% |
2017 | -88.19% | -90.62% |
2016 | -940.60% | 109.1% |
2015 | -449.84% | |
2013 | -1,578.97% | -16797.76% |
2012 | 9.46% | -80.52% |
2011 | 48.53% | -304.06% |
2010 | -23.78% | -98.53% |
2009 | -1,614.83% | -27.56% |
2008 | -2,229.26% | -86.84% |
2007 | -16,936.19% | 6098.17% |
2006 | -273.25% | 1425.49% |
2005 | -17.91% | -66.61% |
2004 | -53.65% | 147.89% |
2003 | -21.64% | -95.87% |
2002 | -523.89% | 487.29% |
2001 | -89.21% |
Company | Operating Margin | Operating Margin differencediff. | Country |
---|---|---|---|
Pfizer PFE | 34.61% | 141.02% | ๐บ๐ธ USA |
AbbVie ABBV | 18.65% | 29.87% | ๐บ๐ธ USA |
Eli Lilly LLY | 24.66% | 71.73% | ๐บ๐ธ USA |
Repligen
RGEN | 27.34% | 90.39% | ๐บ๐ธ USA |
Athersys ATHX | -1,576.98% | -11,081.75% | ๐บ๐ธ USA |
ANI Pharmaceuticals ANIP | -9.64% | -167.13% | ๐บ๐ธ USA |
Palatin Technologies PTN | -2,465.05% | -17,266.09% | ๐บ๐ธ USA |
Royalty Pharma RPRX | 27.89% | 94.22% | ๐ฌ๐ง UK |
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.